Abstract: This invention relates to antibacterial drug compounds containing a bicyclic core, typically a bicycle in which one of the rings is an oxazolidinone. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the compounds in treating bacterial infections and in methods of treating bacterial infections.
Type:
Application
Filed:
February 8, 2017
Publication date:
February 21, 2019
Inventors:
Ian Cooper, Amanda Lyons, David Orr, James Kirkham, Kevin Blades
Abstract: Disclosed are boron mimics of amino acids which are compounds, salts, solvates, or stereoisomers of the Formula (I): wherein A, R1, R2, and R3 are defined herein, and processes for the preparation of the compounds, salts, solvates, or stereoisomers. The compounds, salts, solvates, or stereoisomers of Formula (I) may be used in boron neutron capture therapy. The compounds, salts, solvates, or stereoisomers of Formula (I) with at least one fluorine being, 18F are useful for imaging tumors using positron emission tomography and for evaluating the treatment potential of anti-cancer drugs.
Type:
Application
Filed:
April 29, 2016
Publication date:
February 21, 2019
Applicants:
The United States of America, as represented by the Secretary, Department of Health and Human, and Human Services
Abstract: The invention relates to chemical compound of the general structure [A-R3—X—R4] where A=[R1-R2] or [R1] R1=aryl, heteroaryl R2=alkyl, aryl, heteroaryl, carbonyl, thiocarbonyl, alkyl ester, alkyl thioester R3=O, S, NH X=closo- or nido-boron cluster R4= where Z=OH, SH, NH2 where R5 is selected from H, alkyl, aryl, heteroaryl, alkyl ether, alkyl thioether, alkylamine and R6 is selected from alkyl, aryl, heteroaryl, alkyl ether, alkyl thioether, alkylamine and where R3 and R4 are in meta or para positions to one another, to a process for preparation thereof and to the use thereof, especially in medicine, for example in the inhibition of lipoxygenase.
Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
Type:
Application
Filed:
August 24, 2018
Publication date:
February 21, 2019
Inventors:
Mark E. GURNEY, Timothy J. HAGEN, Xuesheng MO, A. Samuel VELLEKOOP, Donna L. ROMERO, Robert F. CAMPBELL, Joel R. WALKER, Lei ZHU
Abstract: A process for preparing a triazine-based precursor for producing a micro-particulate complex containing a far infrared-emissive silica particle comprises steps of: a) subjecting 2-4-6-trichloro-1,3,5-triazine and a first nucleophilic compound to a displacement reaction in the presence of a first solvent at a first temperature range to form an intermediate; and b) subjecting the intermediate and a second nucleophilic compound to a further displacement reaction in the presence of a second solvent at a second temperature range higher than the first temperature range.
Abstract: Organomodified monosilyl compounds as defined herein exhibit excellent resistance to hydrolysis over a wide range of pH and excellent wetting properties. The organomodified monosilyl compounds are advantageously employed as wetting agents in any of a wide variety of products such as agrochemical compositions, cosurfactants, coatings, personal care products and home care products.
Abstract: Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.
Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HBV and/or HDV and/or HIV infection with one or more nucleotide analogs
Type:
Application
Filed:
March 9, 2017
Publication date:
February 21, 2019
Inventors:
Leonid BEIGELMAN, Guangyi WANG, Minghong ZHONG
Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
Type:
Application
Filed:
March 12, 2018
Publication date:
February 21, 2019
Inventors:
David W.K. KWOK, Nikolay Mintchev STOYNOV
Abstract: Disclosed herein is a process for preparing nicotinamide riboside (NR) from an NR precursor and a phosphate-binding agent in a solvent. The reaction-derived mixture comprising NR may be further used without further processing in a variety of products, particularly in a cosmetic product.
Type:
Application
Filed:
February 21, 2017
Publication date:
February 21, 2019
Inventors:
Dmitri GELMAN, Amani ZOABI, Assaf ZEIRA, Raed ABU-REZIQ
Abstract: The present invention relates to ionic liquids for use in chemical applications and capable of serving the dual function of solvent and liquid support. The ionic liquid lends itself to a method of synthesizing oligomers selected from the group consisting of oligopeptides, oligosaccharides and oligonucleotides, comprising contacting a first monomer unit with an ionic liquid at reaction conditions to provide an ionic liquid bound monomer unit; and contacting the ionic liquid bound monomer unit with at least one further monomer unit at reaction conditions to provide an ionic liquid bound oligomer comprising from 2 to 30 monomer units. The method lends itself to large scale manufacture of oligopeptides, oligosaccharides and oligonucleotides.
Type:
Application
Filed:
August 27, 2018
Publication date:
February 21, 2019
Inventors:
Tak-Hang Chan, Masad J. Damha, Weishi Miao, Robert Alexander Donga, Xun He
Abstract: A class of phosphorus containing polycyclic compounds of general formula I, of general formula I? or of general formula I?, wherein B1, B2, R1, R2, R1?, X1, X2, Y1, Y2, BL1, BL2, Z1, and Z2 are defined herein, that may be useful as modulators of type I interferon production, specifically as STING modulating agents, are provided. Also, provided are use of such compounds.
Abstract: The present invention relates to an improved process for the preparation of Linaclotide of Formula I. The process disclosed in the present invention is simple, economical and eco-friendly with reduced reaction times.
Abstract: The present invention includes methods of improving proteolytic stability of a polypeptide, comprising alkylating at least one selected from the group consisting of a N-terminus amino group, the NH group of the N-terminus first internal amide bond, another primary amino group, a thiol group and a thioether group within the polypeptide. The present invention further includes polypeptides incorporating such chemical modifications.
Type:
Application
Filed:
October 28, 2016
Publication date:
February 21, 2019
Applicants:
TUFTS UNIVERSITY, TUFTS MEDICAL CENTER
Inventors:
KRISHNA KUMAR, VITTORIO MONTANARI, MARTIN BEINBORN, VENKATA RAMAN
Abstract: Disclosed are methods of selective cysteine and selenocysteine modification on peptide/protein molecules under physiologically relevant conditions. The methods feature several advantages over existing methods of peptide modification, such as specifically toward thiols and selenols over other nucleophiles (e.g., amines, hydroxyls), excellent functional group tolerance, and mild reaction conditions.
Type:
Application
Filed:
July 15, 2015
Publication date:
February 21, 2019
Inventors:
Stephen L. Buchwald, Brandley L. Pentelute, Alexander M. Spoloyny, Ekaterina V. Vinogradova, Chi Zhang
Abstract: A method of refolding proteins expressed in non-mammalian cells present in concentrations of 2.0 g/L or higher is disclosed. The method comprises identifying the thiol pair ratio and the redox buffer strength to achieve conditions under which efficient folding at concentrations of 2.0 g/L or higher is achieved and can be employed over a range of volumes, including commercial scale.
Type:
Application
Filed:
February 6, 2018
Publication date:
February 21, 2019
Inventors:
Joseph Edward SHULTZ, Roger HART, Ronald Nixon KEENER, III
Abstract: Methods of producing multiple protein products from blood-based materials including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins are described herein. The inventive methods include steps of: salt fractionation, chromatography, ultrafiltration, diafiltration, solvent-detergent treatment, and sterile filtration. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields. The sequence of process steps can be selected to obtain multiple products from various in-process materials, such as supernatants, pastes, chromatography flow-though, and chromatography washes.
Type:
Application
Filed:
August 10, 2017
Publication date:
February 21, 2019
Inventors:
Eugene Zurlo, David Peter Nowotnik, Charles Heldebrant, Dennis Curtin
Abstract: The present disclosure relates to compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the invention include aza-peptide aldehyde and ketone compositions that inhibit proteases. The disclosed compounds, pharmaceutically acceptable salts, pharmaceutically acceptable derivatives, prodrugs, or combinations thereof can be used to treat disease or pathological conditions related to the activity of proteases associated with a specific disease or condition.
Type:
Application
Filed:
February 28, 2017
Publication date:
February 21, 2019
Inventors:
Ozlem Dogan EKICI, Christopher HADAD, Thomas CORRIGAN
Abstract: The present invention relates to technical fields of organic chemistry and pharmaceutical chemistry, specifically to water-soluble rapamycin derivatives modified with glutathione. More specifically, the present invention discloses a compound of formula I and the preparation method thereof, wherein R1 and R2 are as defined in the description. The compound of formula I can be used in inducing immunosuppression and in the treatment of diseases such as transplant rejection and solid tumor, etc.
Abstract: The present disclosure is directed to providing a new skin-penetrating peptide, a fusion product with a biologically active substance bound using the same, a cosmetic composition containing the same and a pharmaceutical composition for external application to skin containing the same. The skin-penetrating peptide of the present disclosure is less likely to cause an immune response as compared to existing skin-penetrating peptides and exhibits remarkably improved skin permeability. Therefore, the biologically active substance can be effectively delivered through the skin, particularly through the stratum corneum.
Type:
Application
Filed:
September 9, 2016
Publication date:
February 21, 2019
Inventors:
Je-Min CHOI, Wonju KIM, Ja-Hyun KOO, Jiyun KIM
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Type:
Application
Filed:
November 2, 2018
Publication date:
February 21, 2019
Inventors:
Juliane Walz, Daniel Johannes KOWALEWSKI, Hans-Georg RAMMENSEE, Stefan STEVANOVIC
Abstract: A polypeptide, a DNA molecule encoding the polypeptide, a vector, a preparation method and a use therefor are disclosed. The polypeptide comprises an amino acid sequence represented by formula (I) or formula (II): formula (I) comprises an amino acid sequence represented by SEQ ID NO: 1; formula (II) comprises an amino acid sequence obtained by subjecting the amino acid sequence represented by SEQ ID NO: 1 to modification, substituted, and deletion or addition of one or more amino acids. The polypeptide may be used in the preparation of drugs that treat or prevent diseases related to infections caused by bacteria, and can also be used in the preparation of drugs that promote tissue repair and wound healing.
Type:
Application
Filed:
November 1, 2018
Publication date:
February 21, 2019
Inventors:
Wenxin Li, Zhijian Cao, Yingliang Wu, Zesheng Wang, Song Han
Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
Type:
Application
Filed:
October 20, 2016
Publication date:
February 21, 2019
Inventors:
Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including said immunogens.
Type:
Application
Filed:
May 3, 2018
Publication date:
February 21, 2019
Inventors:
Christian BRANDER, Beatriz MOTHE PUJADAS, Anuska LLANO
Abstract: The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.
Abstract: The inventive subject matter relates to the methods for the induction of immunity and prevention of diarrhea resulting from Escherichia coli. The inventive subject matter also relates to the use Escherichia coli adhesins as immunogens and to the construction of conformationally stability and protease resistant Escherichia coli adhesin constructs useful for inducing immunity to Escherichia coli pathogenic bacteria. The methods provide for the induction of B-cell mediated immunity and for the induction of antibody capable of inhibiting the adherence and colonization of Escherichia coli, including enterotoxigenic Escherichia coli, to human cells.
Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
Type:
Application
Filed:
June 28, 2018
Publication date:
February 21, 2019
Inventors:
Catherine R. O'RIORDAN, William H. BRONDYK
Abstract: Disclosed herein is a therapeutic comprising hypoxia inducible factor-1 alpha (HIF-1?). Also disclosed herein is a method for treating hypoxia or ischemia in a subject in need thereof. The method may comprise administering the vaccine to the subject in need thereof.
Type:
Application
Filed:
October 31, 2018
Publication date:
February 21, 2019
Inventors:
David B. Weiner, Kar Muthumani, Emile Mohler, Geoffrey Ouma
Abstract: Disclosed herein is a gonadotropin fusion protein or a thyroid stimulating hormone fusion protein, a method for preparing the same and use thereof. ?-subunit of the gonadotropin or thyroid stimulating hormone is fused to an Fc fragment directly or indirectly through a linker, and ?-subunit binds to the ?-subunit via an affinity between the ?-subunit and the ?-subunit. The fusion protein has a prolonged half-life and less fluctuating activity.
Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Type:
Application
Filed:
May 18, 2018
Publication date:
February 21, 2019
Inventors:
Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
Abstract: The present invention includes compositions and methods for a modified immune cell or precursor cell thereof comprising an inducible expression system. Also provided are gene edited modified immune cells suitable for T cell therapy. Methods of treatment using modified immune cells of the present invention are also provided.
Abstract: T cell receptors (TCRs) that have higher affinity for the Survivin antigen are provided. The high affinity TCRs were engineered through the generation of mutational libraries of TCRs in a single-chain format, followed by selection for improved stability and affinity on the surface of yeast (i.e. directed evolution). In embodiments, the engineered TCRs can be used in soluble form for targeted delivery in vivo, or as genes introduced into T cells in an adoptive T cell setting.
Type:
Application
Filed:
May 25, 2018
Publication date:
February 21, 2019
Inventors:
Sheena N. Smith, Daniel T. Harris, David M. Kranz
Abstract: Chimeric antigen receptor (CAR) polypeptides are provided comprising an antigen binding domain; a hinge domain; a transmembrane domain and an intracellular signaling domain, wherein the CAR polypeptide binds to a target antigen and wherein the antigen binding domain comprises HCDR sequences from a first antibody that binds to the target antigen and LCDR sequences from a second antibody that binds to the target antigen. In certain aspects, the target antigen is CD123.
Type:
Application
Filed:
October 27, 2016
Publication date:
February 21, 2019
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Radhika THOKALA, Laurence J.N. COOPER, Simon OLIVARES
Abstract: The present invention provides a means capable of efficiently manufacturing a fused substance of an Fc protein and a substance of interest (for example, a peptide). Specifically, the present invention provides an azide group-containing Fc protein represented by formula (1): N3-La-Phe-Lb-Fc??(1) wherein N3 represents an azide group; La represents a bond or a divalent group; Phe represents a residue of phenylalanine or a derivative thereof; Lb represents a lysine residue or an arginine residue, or a peptide linker containing two or more amino acid residues having a lysine residue or an arginine residue at/on the N-terminus; and Fc represents an Fc protein; and the like.
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
November 2, 2018
Publication date:
February 21, 2019
Inventors:
Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
November 2, 2018
Publication date:
February 21, 2019
Inventors:
Andrea MAHR, Toni WEINSCHENK, Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
Abstract: A method for preparing low endotoxin collagen is disclosed. The method includes the following steps: providing an animal skin, removing residual adipose tissues and muscle tissues, swelling the animal skin by alkaline solution, peeling the upper and lower surfaces of the animal skin, hydrolyzing the animal skin by a solution including hydrolase, salting out the low endotoxin collagen by salt solutions, and washing the low endotoxin collagen by alcohols.
Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
Type:
Application
Filed:
November 5, 2018
Publication date:
February 21, 2019
Applicant:
Trellis Bioscience, LLC
Inventors:
Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Reyna J. SIMON, Lauren Opremcak BAKALETZ, Steven David GOODMAN
Abstract: An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
Type:
Application
Filed:
July 27, 2018
Publication date:
February 21, 2019
Applicants:
The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Virginia Patent Foundation,d/b/a University of Virginia Licensing & Ventures Group
Inventors:
Adrian U. Wiestner, Martin W. Skarzynski, Margaret A. Lindorfer, Ronald P. Taylor, Christoph Rader, Berengere Vire
Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
Type:
Application
Filed:
August 17, 2018
Publication date:
February 21, 2019
Inventors:
Kim Suzanne Midwood, Philip Antony Bland-Ward, Nigel Burns, Patrick John Hextall, Susan Rebecca Aungier
Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
Type:
Application
Filed:
October 19, 2018
Publication date:
February 21, 2019
Inventors:
William H. Frey, II, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa, III
Abstract: Multiple-variable dose methods for treating TNFa-related disorders, including Crohn's disease and psoriasis, comprising administering TNFa inhibitors, including TNFa antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
Type:
Application
Filed:
March 8, 2018
Publication date:
February 21, 2019
Inventors:
Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K. Paulson, Joanna Z. Peng
Abstract: Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Type:
Application
Filed:
November 2, 2018
Publication date:
February 21, 2019
Inventors:
Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.
Type:
Application
Filed:
March 9, 2018
Publication date:
February 21, 2019
Applicant:
Iterative Therapeutics, Inc.
Inventors:
Barry G.W. Arnason, Mark A. Jensen, David M. White
Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
Type:
Application
Filed:
August 30, 2018
Publication date:
February 21, 2019
Inventors:
Ugur Sahin, Ozlem Türeci, Christiane Stadler, Julia Holland, Hayat Bähr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
Abstract: The present invention relates to anti-PD-L1 binding members and in particular to monovalent, high potency PD-L1-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of cancer and inflammatory diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
Type:
Application
Filed:
February 24, 2017
Publication date:
February 21, 2019
Applicant:
Cell Medica Switzerland AG
Inventors:
Abdijapar Shamshiev, Titus Kretzschmar, Miriam Droste, Douglas Phillips
Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
Type:
Application
Filed:
August 24, 2018
Publication date:
February 21, 2019
Applicant:
CSL LIMITED
Inventors:
Andrew Donald Nash, Arna Elizabeth Andrews, Manuel Baca, Kirsten Mae Edwards, Matthew Philip Hardy, Con Panousis, Felicity Meredith Dunlop
Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
Type:
Application
Filed:
August 21, 2018
Publication date:
February 21, 2019
Applicant:
Adagene Inc.
Inventors:
Peter Peizhi Luo, Fangyong Du, Yan Li, Guizhong Liu, Jun Chen, Xiaohong She, Peter Cheung
Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
Type:
Application
Filed:
October 29, 2018
Publication date:
February 21, 2019
Inventors:
Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi